Tumour cytochrome P450 and drug activation

L H Patterson, G I Murray

Research output: Contribution to journalLiterature review

134 Citations (Scopus)

Abstract

The expression of drug metabolising cytochrome P450s (CYPs) notably 1A, 1B, 2C, 3A, 2D subfamily members have been identified in a wide range of human cancers. Individual tumour types have distinct P450 profiles as studied by detection of P450 activity, identification of immunoreactive CYP protein and detection of CYP mRNA. Selected P450s, especially CYP1B1, are overexpressed in tumours including cancers of the lung, breast, liver, gastrointestinal tract, prostate, bladder. Several prodrug anti-tumour agents have retrospectively been identified as P450 substrates for which tumour CYP activation may hitherto have been underestimated. Those in clinical use include prodrug alkylating agents (cyclophosphamide, ifosphamide, dacarbazine, procarbazine), Tegafur, a prodrug fluoropyrimidine, methoxymorphylinodoxorubicin, a metabolically activated anthracycline, as well as flutamide and tamoxifen, two non-steroidal hormone receptor antagonists that are significantly more active following CYP-hydroxylation. More exciting is the prospect of developing new agents designed to be selectively dependent on tumour CYP activation. This can be illustrated with P450 activation of the 2-(4-aminophenyl)benzothiazoles exclusively in CYP1A1 inducible tumours. Also of interest is the bioreductive antitumour prodrug AQ4N, a CYP3A substrate that is activated to a cytotoxic metabolite specifically in hypoxic tumour regions.

Original languageEnglish
Pages (from-to)1335-1347
Number of pages13
JournalCurrent Pharmaceutical Design
Volume8
Publication statusPublished - 2002

Keywords

  • HUMAN LIVER-MICROSOMES
  • XENOBIOTIC-METABOLIZING ENZYMES
  • AGENT 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLE DF-203
  • GLUTATHIONE S-TRANSFERASES
  • HUMAN MAMMARY-TUMORS
  • BREAST-CANCER
  • ANTITUMOR-ACTIVITY
  • IMMUNOHISTOCHEMICAL LOCALIZATION
  • IN-VITRO
  • METHOXYMORPHOLINYL DOXORUBICIN

Cite this

Tumour cytochrome P450 and drug activation. / Patterson, L H ; Murray, G I .

In: Current Pharmaceutical Design, Vol. 8, 2002, p. 1335-1347.

Research output: Contribution to journalLiterature review

@article{2ef6d30ee7ff464087a2a4152b8759eb,
title = "Tumour cytochrome P450 and drug activation",
abstract = "The expression of drug metabolising cytochrome P450s (CYPs) notably 1A, 1B, 2C, 3A, 2D subfamily members have been identified in a wide range of human cancers. Individual tumour types have distinct P450 profiles as studied by detection of P450 activity, identification of immunoreactive CYP protein and detection of CYP mRNA. Selected P450s, especially CYP1B1, are overexpressed in tumours including cancers of the lung, breast, liver, gastrointestinal tract, prostate, bladder. Several prodrug anti-tumour agents have retrospectively been identified as P450 substrates for which tumour CYP activation may hitherto have been underestimated. Those in clinical use include prodrug alkylating agents (cyclophosphamide, ifosphamide, dacarbazine, procarbazine), Tegafur, a prodrug fluoropyrimidine, methoxymorphylinodoxorubicin, a metabolically activated anthracycline, as well as flutamide and tamoxifen, two non-steroidal hormone receptor antagonists that are significantly more active following CYP-hydroxylation. More exciting is the prospect of developing new agents designed to be selectively dependent on tumour CYP activation. This can be illustrated with P450 activation of the 2-(4-aminophenyl)benzothiazoles exclusively in CYP1A1 inducible tumours. Also of interest is the bioreductive antitumour prodrug AQ4N, a CYP3A substrate that is activated to a cytotoxic metabolite specifically in hypoxic tumour regions.",
keywords = "HUMAN LIVER-MICROSOMES, XENOBIOTIC-METABOLIZING ENZYMES, AGENT 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLE DF-203, GLUTATHIONE S-TRANSFERASES, HUMAN MAMMARY-TUMORS, BREAST-CANCER, ANTITUMOR-ACTIVITY, IMMUNOHISTOCHEMICAL LOCALIZATION, IN-VITRO, METHOXYMORPHOLINYL DOXORUBICIN",
author = "Patterson, {L H} and Murray, {G I}",
year = "2002",
language = "English",
volume = "8",
pages = "1335--1347",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Tumour cytochrome P450 and drug activation

AU - Patterson, L H

AU - Murray, G I

PY - 2002

Y1 - 2002

N2 - The expression of drug metabolising cytochrome P450s (CYPs) notably 1A, 1B, 2C, 3A, 2D subfamily members have been identified in a wide range of human cancers. Individual tumour types have distinct P450 profiles as studied by detection of P450 activity, identification of immunoreactive CYP protein and detection of CYP mRNA. Selected P450s, especially CYP1B1, are overexpressed in tumours including cancers of the lung, breast, liver, gastrointestinal tract, prostate, bladder. Several prodrug anti-tumour agents have retrospectively been identified as P450 substrates for which tumour CYP activation may hitherto have been underestimated. Those in clinical use include prodrug alkylating agents (cyclophosphamide, ifosphamide, dacarbazine, procarbazine), Tegafur, a prodrug fluoropyrimidine, methoxymorphylinodoxorubicin, a metabolically activated anthracycline, as well as flutamide and tamoxifen, two non-steroidal hormone receptor antagonists that are significantly more active following CYP-hydroxylation. More exciting is the prospect of developing new agents designed to be selectively dependent on tumour CYP activation. This can be illustrated with P450 activation of the 2-(4-aminophenyl)benzothiazoles exclusively in CYP1A1 inducible tumours. Also of interest is the bioreductive antitumour prodrug AQ4N, a CYP3A substrate that is activated to a cytotoxic metabolite specifically in hypoxic tumour regions.

AB - The expression of drug metabolising cytochrome P450s (CYPs) notably 1A, 1B, 2C, 3A, 2D subfamily members have been identified in a wide range of human cancers. Individual tumour types have distinct P450 profiles as studied by detection of P450 activity, identification of immunoreactive CYP protein and detection of CYP mRNA. Selected P450s, especially CYP1B1, are overexpressed in tumours including cancers of the lung, breast, liver, gastrointestinal tract, prostate, bladder. Several prodrug anti-tumour agents have retrospectively been identified as P450 substrates for which tumour CYP activation may hitherto have been underestimated. Those in clinical use include prodrug alkylating agents (cyclophosphamide, ifosphamide, dacarbazine, procarbazine), Tegafur, a prodrug fluoropyrimidine, methoxymorphylinodoxorubicin, a metabolically activated anthracycline, as well as flutamide and tamoxifen, two non-steroidal hormone receptor antagonists that are significantly more active following CYP-hydroxylation. More exciting is the prospect of developing new agents designed to be selectively dependent on tumour CYP activation. This can be illustrated with P450 activation of the 2-(4-aminophenyl)benzothiazoles exclusively in CYP1A1 inducible tumours. Also of interest is the bioreductive antitumour prodrug AQ4N, a CYP3A substrate that is activated to a cytotoxic metabolite specifically in hypoxic tumour regions.

KW - HUMAN LIVER-MICROSOMES

KW - XENOBIOTIC-METABOLIZING ENZYMES

KW - AGENT 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLE DF-203

KW - GLUTATHIONE S-TRANSFERASES

KW - HUMAN MAMMARY-TUMORS

KW - BREAST-CANCER

KW - ANTITUMOR-ACTIVITY

KW - IMMUNOHISTOCHEMICAL LOCALIZATION

KW - IN-VITRO

KW - METHOXYMORPHOLINYL DOXORUBICIN

M3 - Literature review

VL - 8

SP - 1335

EP - 1347

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

ER -